Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed
Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.
AMCP Posters Highlight Clinical, Real-world Application of Trastuzumab, Infliximab Biosimilars
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space
During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.
Jeffery Casberg Previews His Presentations at AMCP 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
Biosimilar October News Roundup: An Interchangeable Biosimilar Approval and More
The second interchangeable biosimilar approval, estimates of biosimilar savings, and competition for ranibizumab biosimilars characterized the month's developments.
IPD Analytics Executive Offers Perspective on Biosimilar Uptake and Policy
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to much more robust savings in recent years, according to Leslie Fish, RPh, PharmD, vice president of pharmacy at IPD Analytics.
AmerisourceBergen/Xcenda Policy Experts Discuss Biosimilar Strategy
Two AmerisourceBergen/Xcenda policy experts discuss the coming wave of pharmacy benefit biosimilars, formulary decisions, pricing transparency, and the Biden Administration’s push for lower-cost biologics.
Survey: Moderate Acceptance of Anti-TNF Biosimilars Among Patients With Immune-Mediated Conditions
Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the Academy of Managed Care Pharmacy 2021 Nexus meeting.
Survey: US Pharmacists Have Homework to Do on Biosimilar Interchangeability
Pharmacists need to brush up on their knowledge of the interchangeable biosimilar designation, investigators said in a survey presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting.
Amgen Executive Discusses Prominent Biosimilar Trends
In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.
Kaiser Permanente Study Demonstrates Equivalence for Mvasi
Investigators tapped health system data to conduct an observational, real-world comparison of bevacizumab (Mvasi) vs the reference product (Avastin).
Study: Investigators Report Superior Adherence, Savings for Biosimilars
Weaker persistency and strong adherence were observed among patients taking biosimilar forms of epoetin alfa and infliximab, among others.
Magellan Rx Pharmacists Explore the Payer Perspective on Oncology Biosimilars
Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.
Study: Step Therapy Contributes to Biosimilar Utilization
Study authors measured savings, conversions to biosimilars, and payer policies for 3 originator brands
New York Medicaid Ramps Up Biosimilar Use
New York Medicaid achieved 78% to 94% biosimilar utilization for 4 originator brands during a focused effort in 2019.
2 Commerce Drive Cranbury, NJ 08512